Accessibility StatementSkip Navigation The majority of adverse events were non-serious and mild or moderate in severity across TEMPO-1 through 3. The incidence of SAEs and deaths were low and comparable between placebo and tavapadon groups. The most common adverse reactions reported in 10% of patients were nausea, headache and dizziness for Parkinson's disease patients without levodopa, and nausea and dyskinesia for patients on adjunctive therapy with levodopa. NORTH CHICAGO, Ill., Sept. 26, 2025 /PRNewswir ...